Razpipadon

Razpipadon (developmental codes CVL-871, PF-06669571, and PW-0464) is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy.^{[1][2][3][4][5]} It is taken orally.^[1]

Other namesCVL-871; CVL871; PF-06669571; PF06669571; PF-6669571; PF6669571; PW-0464; PW0464

Routes of
administrationOral^[1]

Drug classDopamine receptor agonist; Dopamine D₁ and D₅ receptor agonist

CAS Number

• 1643489-35-3

Quick facts Clinical data, Other names ...

Razpipadon

Clinical data
Other names	CVL-871; CVL871; PF-06669571; PF06669571; PF-6669571; PF6669571; PW-0464; PW0464
Routes of administration	Oral[1]
Drug class	Dopamine receptor agonist; Dopamine D1 and D5 receptor agonist
Identifiers
IUPAC name 6-[4-[3-(difluoromethoxy)pyridin-2-yl]oxy-2-methylphenyl]-1,5-dimethylpyrimidine-2,4-dione
CAS Number	1643489-35-3
PubChem CID	86764103
ChemSpider	58945356
UNII	6X6XF88J2M
ChEMBL	ChEMBL3697578
Chemical and physical data
Formula	C19H17F2N3O4
Molar mass	389.359 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC1=C(C=CC(=C1)OC2=C(C=CC=N2)OC(F)F)C3=C(C(=O)NC(=O)N3C)C
InChI InChI=1S/C19H17F2N3O4/c1-10-9-12(27-17-14(28-18(20)21)5-4-8-22-17)6-7-13(10)15-11(2)16(25)23-19(26)24(15)3/h4-9,18H,1-3H3,(H,23,25,26) Key:ZXIPVZWZRQCIRW-UHFFFAOYSA-N

Close

Razpipadon acts as a selective partial agonist of the dopamine D₁ and D₅ receptors.^[1][3][6]

The drug was originated by Pfizer and is under development by Cerevel Therapeutics.^[1][2] As of April 2022, razpipadon is in phase 2 clinical trials for dementia-related apathy.^[1] It was also previously under development for Parkinson's disease and cognition disorders, but development for these indications was discontinued.^[2]